Academy of Physicians
in Clinical Research

Academy of Physicians
in Clinical Research




News from SCRIP

APCR Members can get a free trial to SCRIP and a discount on a SCRIP subscription by contacting John Lezcano from SCRIP directly at the information below. 

John Lezcano
Corporate Account Manager

Pharma intelligence | informa
T: (212) 652-2678
M: (631) 807-4971
John.lezcano@informa.com
pharmaintelligence.informa.com

Cara’s Phase III Success In CKD-Pruritus Puts NDA Filing In Sight

Wed, 05/29/2019 - 1:59pm

Second Phase III study expected later this year, but Cara wants to discuss the possibility of accelerated filing with the...

      Related Stories 

Publisher’s ASCO Spotlight: Compare Your Insights To Oncologists

Wed, 05/29/2019 - 1:05pm

Inspired by next week’s ASCO conference, Informa is crowdsourcing insights from cancer experts, including their predictions on cancer prescribing patterns...

      Related Stories 

France Lifts Clinical Hold From AB Science’s Masitinib

Wed, 05/29/2019 - 7:32am

After two years on clinical hold, the French biotech has resolved quality and pharmacovigilance problems that forced it to suspend...

      Related Stories 

No Panic At Newron Over Delayed Schizophrenia Drug Trial

Wed, 05/29/2019 - 3:12am

Although the US FDA raised concerns about a rat toxicity trial, causing shares to slide, Italy's Newron believes the trial...

      Related Stories 

Mehta Analysis: Welcome to BioPharma 2.0

Wed, 05/29/2019 - 1:55am

Viren Mehta of Mehta Partners LLC ponders what the approval of Novartis gene therapy Zolgensma foreshadows, in terms of future...

      Related Stories 

Value Assessment Vexes Pharma As China Costs Soar, Prices Fall

Tue, 05/28/2019 - 11:09pm

Traditionally a low-cost manufacturing haven, China has seen pharma R&D costs increase rapidly although prices for pharmaceuticals have not gone...

      Related Stories 

J&J Leverages Novel Mechanisms In Neuropsychiatry, Neurodegeneration

Tue, 05/28/2019 - 5:46pm

Janssen Neuroscience therapeutic area head Husseini Manji describes near-, mid- and long-term milestones among J&J's potential blockbusters, including an every...

      Related Stories 

Deal Watch: Lilly Takes Global Rights To Centrexion Non-Opioid Pain Candidate

Tue, 05/28/2019 - 1:56pm

Lilly licenses non-opioid pain candidate from Centrexion. China’s Hansoh gets rights to inibelizumab from AstraZeneca spinout Viela for lead indication...

      Related Stories 

Marinomed Marches Towards Approval For Hay Fever Drug

Tue, 05/28/2019 - 6:35am

With Budesolv hitting key endpoints in a Phase III allergy trial, the Austrian biotech is stepping up its partnership discussions...

      Related Stories 

Daiichi Denies OTC Business Sale But Would It Make Sense?

Sun, 05/26/2019 - 10:49pm

Daiichi Sankyo denies report it is in negotiations to sell its OTC business, but might such a move actually align...

      Related Stories 

In Immunology, J&J Makes A Big Move On Biologic Combinations

Fri, 05/24/2019 - 11:32am

The company has initiated a Phase II study of Tremfya and Simponi in combination for the treatment of ulcerative colitis...

      Related Stories 

Pipeline Watch: Phase III Starts For Nirogacestat, Etrasimod

Fri, 05/24/2019 - 7:25am

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical...

      Related Stories 

GSK Revamps Sales Reps Incentives To Be Competitive In Cancer

Fri, 05/24/2019 - 6:33am

Seven years after a major shift in how the company compensated its sales force, the UK major has done a...

      Related Stories 

AZ, Takeda, Novartis Praised For Medicines Access Work But More Is Needed

Fri, 05/24/2019 - 2:42am

The 20 major companies in the Access to Medicines Index have made progress in areas like inclusive business models, R&D...

      Related Stories 

Pages